Progress for dengue virus diseases: Towards the NS2B-NS3pro inhibition for a therapeutic-based approach

FEBS Journal

Volumn 274, Issue 12, 2007, Pages 2986-3002

  Melino, Sonia ^a   Paci, Maurizio ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Dengue hemorrhagic fever; Dengue virus; NS3; Protease inhibitors; Vaccines; Viral diseases; Viral serine protease

Indexed keywords

4 HYDROXYPANDURATIN A; ACETYLSALICYLIC ACID; ALDEHYDE DERIVATIVE; ALPHA INTERFERON; AMIDE; ANTIVIRUS AGENT; BETA INTERFERON; BORONIC ACID DERIVATIVE; CAPSID PROTEIN; CHALCONE DERIVATIVE; DENGUE VACCINE; DNA VACCINE; GAMMA INTERFERON; HEPARIN; INACTIVATED VACCINE; KETONE DERIVATIVE; LIVE VACCINE; NONSTRUCTURAL PROTEIN 2B; NONSTRUCTURAL PROTEIN 3; PANDURATIN A; POLYSACCHARIDE SULFATE; PROTEINASE; PROTEINASE INHIBITOR; RECOMBINANT VACCINE; RIBAVIRIN; SALICYLATE SODIUM; UNCLASSIFIED DRUG; VIRUS PROTEIN; YELLOW FEVER VACCINE;

AMINO ACID SEQUENCE; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; COMPETITIVE INHIBITION; CRYSTAL STRUCTURE; DENGUE; DENGUE VIRUS; DRUG TARGETING; ENZYME SPECIFICITY; ENZYME STRUCTURE; ENZYME SUBSTRATE; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEINASE INHIBITION; REVIEW; VIRUS IMMUNITY; VIRUS INHIBITION; VIRUS MORPHOLOGY; VIRUS REPLICATION;

AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; DENGUE; DENGUE HEMORRHAGIC FEVER; DENGUE VACCINES; DENGUE VIRUS; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; SERINE ENDOPEPTIDASES; SUBSTRATE SPECIFICITY; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION; WORLD HEALTH ORGANIZATION;

AEDES AEGYPTI; DENGUE VIRUS;

EID: 34249799052     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2007.05831.x     Document Type: Review

References (135)

1. Bancroft FW (1906) On the influence of the relative concentration of calcium ions on the reversal of the polar effects of the galvanic current in paramecium. J Physiol 34, 444 463.
2. Lindenbach BD Rice CM (2001) Flaviviridae: the viruses and their replication. In Fundamental Virology (Knipe DM Howley PM, eds), pp. 991 1041. Lippincott Williams & Wilkins, Philadelphia, PA.
3. Henchal EA Putnak JR (1990) The dengue viruses. Clin Microbiol Rev 3, 376 396.
4. Kautner I, Robinson MJ Kuhnle U (1997) Dengue virus infection: epidemiology, pathogenesis, clinical presentation, diagnosis, and prevention. J Pediatr 131, 516 524.
5. Halstead SB (1988) Pathogenesis of dengue: challenges to molecular biology. Science 239, 476 481.
6. Kliks SC, Nisalak A, Brandt WE, Wahl L Burke DS (1989) Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg 40, 444 451.
7. Morens DM (1994) Antibody-dependent enhancement of infection and the pathogenesis of viral disease. Clin Infect Dis 19, 500 512.
8. Watts DM, Porter KR, Putvatana P, Vasquez B, Calampa C, Hayes CG Halstead SB (1999) Failure of secondary infection with American genotype dengue 2 to cause dengue haemorrhagic fever. Lancet 354, 1431 1434.
9. Cahour A, Pletnev A, Vazielle-Falcoz M, Rosen L Lai CJ (1995) Growth-restricted dengue virus mutants containing deletions in the 5′ noncoding region of the RNA genome. Virology 207, 68 76.
10. Zeng L, Falgout B Markoff L (1998) Identification of specific nucleotide sequences within the conserved 3′-SL in the dengue type 2 virus genome required for replication. J Virol 72, 7510 7522.
11. Chiu WW, Kinney RM Dreher TW (2005) Control of translation by the 5′- and 3′-terminal regions of the dengue virus genome. J Virol 79, 8303 8315.
12. Littaua R, Kurane I Ennis FA (1990) Human IgG Fc receptor II mediates antibody-dependent enhancement of dengue virus infection. J Immunol 144, 3183 3186.
13. Heinz FX, Auer G, Stiasny K, Holzmann H, Mandl C, Guirakhoo F Kunz C (1994) The interactions of the flavivirus envelope proteins: implications for virus entry and release. Arch Virol Suppl. 9, 339 348.
14. Heinz FX Allison SL (2001) The machinery for flavivirus fusion with host cell membranes. Curr Opin Microbiol 4, 450 455.
15. Zhang N, Chen HM, Koch V, Schmitz H, Liao CL, Bretner M, Bhadti VS, Fattom AI, Naso RB, Hosmane RS et al. (2003) Ring-expanded ('fat') nucleoside and nucleotide analogues exhibit potent in vitro activity against flaviviridae NTPases/helicases, including those of the West Nile virus, hepatitis C virus, and Japanese encephalitis virus. J Med Chem 46, 4149 4164.
16. Allison SL, Schalich J, Stiasny K, Mandl CW Heinz FX (2001) Mutational evidence for an internal fusion peptide in flavivirus envelope protein E. J Virol 75, 4268 4275.
17. Beasley DW Aaskov JG (2001) Epitopes on the dengue 1 virus envelope protein recognized by neutralizing IgM monoclonal antibodies. Virology 279, 447 458.
18. Lorenz IC, Allison SL, Heinz FX Helenius A (2002) Folding and dimerization of tick-borne encephalitis virus envelope proteins prM and E in the endoplasmic reticulum. J Virol 76, 5480 5491.
19. Wengler G (1989) An analysis of the antibody response against West Nile virus E protein purified by SDS-PAGE indicates that this protein does not contain sequential epitopes for efficient induction of neutralizing antibodies. J Gen Virol 70, 987 992.
20. Allison SL, Stadler K, Mandl CW, Kunz C Heinz FX (1995) Synthesis and secretion of recombinant tick-borne encephalitis virus protein E in soluble and particulate form. J Virol 69, 5816 5820.
21. Rey FA, Heinz FX, Mandl C, Kunz C Harrison SC (1995) The envelope glycoprotein from tick-borne encephalitis virus at 2 Å resolution. Nature 375, 291 298.
22. Falgout B Markoff L (1995) Evidence that flavivirus NS1-NS2A cleavage is mediated by a membrane-bound host protease in the endoplasmic reticulum. J Virol 69, 7232 7243.
23. Chambers TJ, Hahn CS, Galler R Rice CM (1990) Flavivirus genome organization, expression, and replication. Annu Rev Microbiol 44, 649 688.
24. Mackenzie JM, Jones MK Young PR (1996) Immunolocalization of the dengue virus nonstructural glycoprotein NS1 suggests a role in viral RNA replication. Virology 220, 232 240.
25. Jacobs MG, Robinson PJ, Bletchly C, Mackenzie JM Young PR (2000) Dengue virus nonstructural protein 1 is expressed in a glycosyl- phosphatidylinositol- linked form that is capable of signal transduction. Faseb J 14, 1603 1610.
26. Falgout B, Pethel M, Zhang YM Lai CJ (1991) Both nonstructural proteins NS2B and NS3 are required for the proteolytic processing of dengue virus nonstructural proteins. J Virol 65, 2467 2475.
27. Gorbalenya AE, Donchenko AP, Koonin EV Blinov VM (1989) N-terminal domains of putative helicases of flavi- and pestiviruses may be serine proteases. Nucleic Acids Res 17, 3889 3897.
28. Li H, Clum S, You S, Ebner KE Padmanabhan R (1999) The serine protease and RNA-stimulated nucleoside triphosphatase and RNA helicase functional domains of dengue virus type 2 NS3 converge within a region of 20 amino acids. J Virol 73, 3108 3116.
29. Wengler G (1993) The NS 3 nonstructural protein of flaviviruses contains an RNA triphosphatase activity. Virology 197, 265 273.
30. Cui T, Sugrue RJ, Xu Q, Lee AK, Chan YC Fu J (1998) Recombinant dengue virus type 1 NS3 protein exhibits specific viral RNA binding and NTPase activity regulated by the NS5 protein. Virology 246, 409 417.
31. Arias CF, Preugschat F Strauss JH (1993) Dengue 2 virus NS2B and NS3 form a stable complex that can cleave NS3 within the helicase domain. Virology 193, 888 899.
32. Lobigs M (1993) Flavivirus premembrane protein cleavage and spike heterodimer secretion require the function of the viral proteinase NS3. Proc Natl Acad Sci USA 90, 6218 6222.
33. Teo KF Wright PJ (1997) Internal proteolysis of the NS3 protein specified by dengue virus 2. J Gen Virol 78, 337 341.
34. Koonin EV (1993) Computer-assisted identification of a putative methyltransferase domain in NS5 protein of flaviviruses and lambda 2 protein of reovirus. J Gen Virol 74, 733 740.
35. Tan BH, Fu J, Sugrue RI, Yap EH, Chan YC Tan YH (1996) Recombinant dengue type 1 virus NS5 protein expressed in Escherichia coli exhibits RNA-dependent RNA polymerase activity. Virology 216, 317 325.
36. Halstead SB Deen J (2002) The future of dengue vaccines. Lancet 360, 1243 1245.
37. Hombach J, Barrett AD, Cardosa MJ, Deubel V, Guzman M, Kurane I, Roehrig JT, Sabchareon A Kieny MP (2005) Review on flavivirus vaccine development. Proceedings of a meeting jointly organised by the World Health Organization and the Thai Ministry of Public Health, 26-27 April 2004, Bangkok, Thailand. Vaccine 23, 2689 2695.
38. Stephenson JR (2005) Understanding dengue pathogenesis: implications for vaccine design. Bull World Health Organ 83, 308 314.
39. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, Endy TP, Raengsakulrach B, Rothman AL, Ennis FA et al. (2000) Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 181, 2 9.
40. Guirakhoo F, Pugachev K, Zhang Z, Myers G, Levenbook I, Draper K, Lang J, Ocran S, Mitchell F, Parsons M et al. (2004) Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol 78, 4761 4775.
41. Donnelly JJ, Ulmer JB, Shiver JW Liu MA (1997) DNA vaccines. Annu Rev Immunol 15, 617 648.
42. Schultz J, Dollenmaier G Molling K (2000) Update on antiviral DNA vaccine research (1998-2000). Intervirology 43, 197 217.
43. Chang GJ, Davis BS, Hunt AR, Holmes DA Kuno G (2001) Flavivirus DNA vaccines: current status and potential. Ann N Y Acad Sci 951, 272 285.
44. Raviprakash K, Marques E, Ewing D, Lu Y, Phillips I, Porter KR, Kochel TJ, August TJ, Hayes CG Murphy GS (2001) Synergistic neutralizing antibody response to a dengue virus type 2 DNA vaccine by incorporation of lysosome-associated membrane protein sequences and use of plasmid expressing GM-CSF. Virology 290, 74 82.
45. Barrett AD (2001) Current status of flavivirus vaccines. Ann NY Acad Sci 951, 262 271.
46. Putnak R, Porter K Schmaljohn C (2003) DNA vaccines for flaviviruses. Adv Virus Res 61, 445 468.
47. Konishi E, Kosugi S Imoto J (2006) Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice. Vaccine 24, 2200 2207.
48. Mathew A, Kurane I, Green S, Stephens HA, Vaughn DW, Kalayanarooj S, Suntayakorn S, Chandanayingyong D, Ennis FA Rothman AL (1998) Predominance of HLA-restricted cytotoxic T-lymphocyte responses to serotype-cross-reactive epitopes on nonstructural proteins following natural secondary dengue virus infection. J Virol 72, 3999 4004.
49. Kurane I Ennis FA (1994) Cytotoxic T lymphocytes in dengue virus infection. Curr Top Microbiol Immunol 189, 93 108.
50. Kurane I, Brinton MA, Samson AL Ennis FA (1991) Dengue virus-specific, human CD4+ CD8- cytotoxic T-cell clones: multiple patterns of virus cross-reactivity recognized by NS3-specific T-cell clones. J Virol 65, 1823 1828.
51. Gagnon SJ, Ennis FA Rothman AL (1999) Bystander target cell lysis and cytokine production by dengue virus-specific human CD4(+) cytotoxic T-lymphocyte clones. J Virol 73, 3623 3629.
52. Kaufman BM, Summers PL, Dubois DR Eckels KH (1987) Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection. Am J Trop Med Hyg 36, 427 434.
53. Kaufman BM, Summers PL, Dubois DR, Cohen WH, Gentry MK, Timchak RL, Burke DS Eckels KH (1989) Monoclonal antibodies for dengue virus prM glycoprotein protect mice against lethal dengue infection. Am J Trop Med Hyg 41, 576 580.
54. Brandriss MW, Schlesinger JJ, Walsh EE Briselli M (1986) Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses. J Gen Virol 67, 229 234.
55. Tan CH, Yap EH, Singh M, Deubel V Chan YC (1990) Passive protection studies in mice with monoclonal antibodies directed against the non-structural protein NS3 of dengue 1 virus. J Gen Virol 71, 745 749.
56. Feighny R, Burrous J, McCown J, Hoke C Putnak R (1992) Purification of native dengue-2 viral proteins and the ability of purified proteins to protect mice. Am J Trop Med Hyg 47, 405 412.
57. Gould EA, Buckley A, Barrett AD Cammack N (1986) Neutralizing (54K) and non-neutralizing (54K and 48K) monoclonal antibodies against structural and non-structural yellow fever virus proteins confer immunity in mice. J Gen Virol 67, 591 595.
58. Schlesinger JJ, Brandriss MW Walsh EE (1987) Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1. J Gen Virol 68, 853 857.
59. Falconar AK (1997) The dengue virus nonstructural-1 protein (NS1) generates antibodies to common epitopes on human blood clotting, integrin/adhesin proteins and binds to human endothelial cells: potential implications in haemorrhagic fever pathogenesis. Arch Virol 142, 897 916.
60. Konishi E, Yamaoka M, Kurane I Mason PW (2000) A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice. Vaccine 18, 1133 1139.
61. Konishi E Fujii A (2002) Dengue type 2 virus subviral extracellular particles produced by a stably transfected mammalian cell line and their evaluation for a subunit vaccine. Vaccine 20, 1058 1067.
62. Konishi E, Terazawa A Imoto J (2003) Simultaneous immunization with DNA and protein vaccines against Japanese encephalitis or dengue synergistically increases their own abilities to induce neutralizing antibody in mice. Vaccine 21, 1826 1832.
63. Lazo L, Hermida L, Zulueta A, Sanchez J, Lopez C, Silva R, Guillen G Guzman MG (2007) A recombinant capsid protein from Dengue-2 induces protection in mice against homologous virus. Vaccine 25, 1064 1070.
64. Chen Y, Maguire T, Hileman RE, Fromm JR, Esko JD, Linhardt RJ Marks RM (1997) Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat Med 3, 866 871.
65. Germi R, Crance JM, Garin D, Guimet J, Lortat-Jacob H, Ruigrok RW, Zarski JP Drouet E (2002) Heparan sulfate-mediated binding of infectious dengue virus type 2 and yellow fever virus. Virology 292, 162 168.
66. Damonte EB, Matulewicz MC Cerezo AS (2004) Sulfated seaweed polysaccharides as antiviral agents. Curr Med Chem 11, 2399 2419.
67. Talarico LB, Zibetti RG, Faria PC, Scolaro LA, Duarte ME, Noseda MD, Pujol CA Damonte EB (2004) Anti-herpes simplex virus activity of sulfated galactans from the red seaweeds Gymnogongrus griffithsiae and Cryptonemia crenulata. Int J Biol Macromol 34, 63 71.
68. Pujol CA, Estevez JM, Carlucci MJ, Ciancia M, Cerezo AS Damonte EB (2002) Novel dl-galactan hybrids from the red seaweed Gymnogongrus torulosus are potent inhibitors of herpes simplex virus and dengue virus. Antivir Chem Chemother 13, 83 89.
69. Shigeta S, Mori S, Kodama E, Kodama J, Takahashi K Yamase T (2003) Broad spectrum anti-RNA virus activities of titanium and vanadium substituted polyoxotungstates. Antiviral Res 58, 265 271.
70. Liao CL, Lin YL, Wu BC, Tsao CH, Wang MC, Liu CI, Huang YL, Chen JH, Wang JP Chen LK (2001) Salicylates inhibit flavivirus replication independently of blocking nuclear factor kappa B activation. J Virol 75, 7828 7839.
71. Courageot MP, Catteau A Despres P (2003) Mechanisms of dengue virus-induced cell death. Adv Virus Res 60, 157 186.
72. Myint KS, Endy TP, Mongkolsirichaikul D, Manomuth C, Kalayanarooj S, Vaughn DW, Nisalak A, Green S, Rothman AL, Ennis FA et al. (2006) Cellular immune activation in children with acute dengue virus infections is modulated by apoptosis. J Infect Dis 194, 600 607.
73. Crance JM, Scaramozzino N, Jouan A Garin D (2003) Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses. Antiviral Res 58, 73 79.
74. Diamond MS, Roberts TG, Edgil D, Lu B, Ernst J Harris E (2000) Modulation of Dengue virus infection in human cells by alpha, beta, and gamma interferons. J Virol 74, 4957 4966.
75. Diamond MS Harris E (2001) Interferon inhibits dengue virus infection by preventing translation of viral RNA through a PKR-independent mechanism. Virology 289, 297 311.
76. Bartholomeusz A, Tomlinson E, Wright PJ, Birch C, Locarnini S, Weigold H, Marcuccio S Holan G (1994) Use of a flavivirus RNA-dependent RNA polymerase assay to investigate the antiviral activity of selected compounds. Antiviral Res 24, 341 350.
77. Neves-Souza PC, Azeredo EL, Zagne SM, Valls-de-Souza R, Reis SR, Cerqueira DI, Nogueira RM Kubelka CF (2005) Inducible nitric oxide synthase (iNOS) expression in monocytes during acute Dengue Fever in patients and during in vitro infection. BMC Infect Dis 5, 64.
78. Charnsilpa W, Takhampunya R, Endy TP, Mammen MP Jr., Libraty DH Ubol S (2005) Nitric oxide radical suppresses replication of wild-type dengue 2 viruses in vitro. J Med Virol 77, 89 95.
79. Takhampunya R, Padmanabhan R Ubol S (2006) Antiviral action of nitric oxide on dengue virus type 2 replication. J Gen Virol 87, 3003 3011.
80. Valle RP Falgout B (1998) Mutagenesis of the NS3 protease of dengue virus type 2. J Virol 72, 624 632.
81. Krausslich HG Wimmer E (1988) Viral proteinases. Annu Rev Biochem 57, 701 754.
82. Babe LM Craik CS (1997) Viral proteases: evolution of diverse structural motifs to optimize function. Cell 91, 427 430.
83. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Jonas L, Meibohm A, Holder D, Schleif WA et al. (1998) Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. JAMA 280, 35 41.
84. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ Jr., Feinberg JE, Balfour HH Jr., Deyton LR et al. (1997) A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 337, 725 733.
85. Patick AK Potts KE (1998) Protease inhibitors as antiviral agents. Clin Microbiol Rev 11, 614 627.
86. Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P, Bos M, Cameron DR, Cartier M, Cordingley MG et al. (2003) An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426, 186 189.
87. Perni RB, Almquist SJ, Byrn RA, Chandorkar G, Chaturvedi PR, Courtney LF, Decker CJ, Dinehart K, Gates CA, Harbeson SL et al. (2006) Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother 50, 899 909.
88. Tong L (2002) Viral proteases. Chem Rev 102, 4609 4626.
89. Love RA, Parge HE, Wickersham JA, Hostomsky Z, Habuka N, Moomaw EW, Adachi T Hostomska Z (1996) The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell 87, 331 342.
90. Shimizu Y, Yamaji K, Masuho Y, Yokota T, Inoue H, Sudo K, Satoh S Shimotohno K (1996) Identification of the sequence on NS4A required for enhanced cleavage of the NS5A/5B site by hepatitis C virus NS3 protease. J Virol 70, 127 132.
91. Cahour A, Falgout B Lai CJ (1992) Cleavage of the dengue virus polyprotein at the NS3/NS4A and NS4B/NS5 junctions is mediated by viral protease NS2B-NS3, whereas NS4A/NS4B may be processed by a cellular protease. J Virol 66, 1535 1542.
92. Mukhopadhyay S, Kuhn RJ Rossmann MG (2005) A structural perspective of the flavivirus life cycle. Nat Rev Microbiol 3, 13 22.
93. Beasley DW (2005) Recent advances in the molecular biology of west nile virus. Curr Mol Med 5, 835 850.
94. Chambers TJ, Nestorowicz A, Amberg SM Rice CM (1993) Mutagenesis of the yellow fever virus NS2B protein: effects on proteolytic processing, NS2B-NS3 complex formation, and viral replication. J Virol 67, 6797 6807.
95. Paetzel M Dalbey RE (1997) Catalytic hydroxyl/amine dyads within serine proteases. Trends Biochem Sci 22, 28 31.
96. Schechter I Berger A (1967) On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun 27, 157 162.
97. Amberg SM Rice CM (1998) Flavivirin. In Handbook of Proteolytic Enzymes (Barret AJ, Rawlings ND Woessner JF, eds), pp. 000 000. Academic Press, London.
98. Chambers TJ, Weir RC, Grakoui A, McCourt DW, Bazan JF, Fletterick RJ Rice CM (1990) Evidence that the N-terminal domain of nonstructural protein NS3 from yellow fever virus is a serine protease responsible for site-specific cleavages in the viral polyprotein. Proc Natl Acad Sci USA 87, 8898 8902.
99. Bartenschlager R, Lohmann V, Wilkinson T Koch JO (1995) Complex formation between the NS3 serine-type proteinase of the hepatitis C virus and NS4A and its importance for polyprotein maturation. J Virol 69, 7519 7528.
100. Chambers TJ, Grakoui A Rice CM (1991) Processing of the yellow fever virus nonstructural polyprotein: a catalytically active NS3 proteinase domain and NS2B are required for cleavages at dibasic sites. J Virol 65, 6042 6050.
101. Preugschat F, Yao CW Strauss JH (1990) In vitro processing of dengue virus type 2 nonstructural proteins NS2A, NS2B, and NS3. J Virol 64, 4364 4374.
102. Preugschat F Strauss JH (1991) Processing of nonstructural proteins NS4A and NS4B of dengue 2 virus in vitro and in vivo. Virology 185, 689 697.
103. Brinkworth RI, Fairlie DP, Leung D Young PR (1999) Homology model of the dengue 2 virus NS3 protease: putative interactions with both substrate and NS2B cofactor. J Gen Virol 80, 1167 1177.
104. Falgout B, Miller RH Lai CJ (1993) Deletion analysis of dengue virus type 4 nonstructural protein NS2B: identification of a domain required for NS2B-NS3 protease activity. J Virol 67, 2034 2042.
105. Leung D, Schroder K, White H, Fang NX, Stoermer MJ, Abbenante G, Martin JL, Young PR Fairlie DP (2001) Activity of recombinant dengue 2 virus NS3 protease in the presence of a truncated NS2B co-factor, small peptide substrates, and inhibitors. J Biol Chem 276, 45762 45771.
106. Yusof R, Clum S, Wetzel M, Murthy HM Padmanabhan R (2000) Purified NS2B/NS3 serine protease of dengue virus type 2 exhibits cofactor NS2B dependence for cleavage of substrates with dibasic amino acids in vitro. J Biol Chem 275, 9963 9969.
107. Melino S, Fucito S, Campagna A, Wrubl F, Gamarnik A, Cicero DO Paci M (2006) The active essential CFNS3d protein complex. FEBS J 273, 3650 3662.
108. Butkiewicz NJ, Yao N, Wright-Minogue J, Zhang R, Ramanathan L, Lau JY, Hong Z Dasmahapatra B (2000) Hepatitis C NS3 protease: restoration of NS4A cofactor activity by N-biotinylation of mutated NS4A using synthetic peptides. Biochem Biophys Res Commun 267, 278 282.
109. Niyomrattanakit P, Winoyanuwattikun P, Chanprapaph S, Angsuthanasombat C, Panyim S Katzenmeier G (2004) Identification of residues in the dengue virus type 2 NS2B cofactor that are critical for NS3 protease activation. J Virol 78, 13708 13716.
110. Clum S, Ebner KE Padmanabhan R (1997) Cotranslational membrane insertion of the serine proteinase precursor NS2B-NS3 (Pro) of dengue virus type 2 is required for efficient in vitro processing and is mediated through the hydrophobic regions of NS2B. J Biol Chem 272, 30715 30723.
111. Westaway EG, Mackenzie JM, Kenney MT, Jones MK Khromykh AA (1997) Ultrastructure of Kunjin virus-infected cells: colocalization of NS1 and NS3 with double-stranded RNA, and of NS2B with NS3, in virus-induced membrane structures. J Virol 71, 6650 6661.
112. Kim JL, Morgenstern KA, Lin C, Fox T, Dwyer MD, Landro JA, Chambers SP, Markland W, Lepre CA, O'Malley ET et al. (1996) Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 87, 343 355.
113. Yan BS, Tam MH Syu WJ (1998) Self association of the C-terminal domain of the hepatitis-C virus core protein. Eur J Biochem 258, 100 106.
114. Barbato G, Cicero OD, Nardi MC, Steinkuler C, Cortese R, De Francesco R Bazzo R (1999) The solution structure of the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3-protein provides new insights into its activation and catalytic mechanism. J Mol Biol 289, 371 384.
115. Murthy HM, Clum S Padmanabhan R (1999) Dengue virus NS3 serine protease. Crystal structure and insights into interaction of the active site with substrates by molecular modeling and structural analysis of mutational effects. J Biol Chem 274, 5573 5580.
116. Murthy HM, Judge K, DeLucas L Padmanabhan R (2000) Crystal structure of Dengue virus NS3 protease in complex with a Bowman-Birk inhibitor: implications for flaviviral polyprotein processing and drug design. J Mol Biol 301, 759 767.
117. Erbel P, Schiering N, D'Arcy A, Renatus M, Kroemer M, Lim SP, Yin Z, Keller TH, Vasudevan SG Hommel U (2006) Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus. Nat Struct Mol Biol 13, 372 373.
118. Kuyumcu-Martinez NM, Joachims M Lloyd RE (2002) Efficient cleavage of ribosome-associated poly (A)-binding protein by enterovirus 3C protease. J Virol 76, 2062 2074.
119. Glaser W, Cencic R Skern T (2001) Foot-and-mouth disease virus leader proteinase: involvement of C-terminal residues in self-processing and cleavage of eIF4GI. J Biol Chem 276, 35473 35481.
120. Kassel DB, Green MD, Wehbie RS, Swanstrom R Berman J (1995) HIV-1 protease specificity derived from a complex mixture of synthetic substrates. Anal Biochem 228, 259 266.
121. Pessi A (2001) A personal account of the role of peptide research in drug discovery: the case of hepatitis C. J Pept Sci 7, 2 14.
122. Li J, Lim SP, Beer D, Patel V, Wen D, Tumanut C, Tully DC, Williams JA, Jiricek J, Priestle JP et al. (2005) Functional profiling of recombinant NS3 proteases from all four serotypes of dengue virus using tetrapeptide and octapeptide substrate libraries. J Biol Chem 280, 28766 28774.
123. Niyomrattanakit P, Yahorava S, Mutule I, Mutulis F, Petrovska R, Prusis P, Katzenmeier G Wikberg JE (2006) Probing the substrate specificity of the dengue virus type 2 NS3 serine protease by using internally quenched fluorescent peptides. Biochem J 397, 203 211.
124. Shiryaev SA, Kozlov IA, Ratnikov BI, Smith JW, Lebl M Strongin AY (2007) Cleavage preference distinguishes the two-component NS2B-NS3 serine proteinases of Dengue and West Nile viruses. Biochem J 401, 743 752.
125. Chappell KJ, Stoermer MJ, Fairlie DP Young PR (2006) Insights to substrate binding and processing by West Nile Virus NS3 protease through combined modeling, protease mutagenesis, and kinetic studies. J Biol Chem 281, 38448 38458.
126. Chanprapaph S, Saparpakorn P, Sangma C, Niyomrattanakit P, Hannongbua S, Angsuthanasombat C Katzenmeier G (2005) Competitive inhibition of the dengue virus NS3 serine protease by synthetic peptides representing polyprotein cleavage sites. Biochem Biophys Res Commun 330, 1237 1246.
127. Edwards PD Bernstein PR (1994) Synthetic inhibitors of elastase. Med Res Rev 14, 127 194.
128. Babine RE Bender SL (1997) Molecular recognition of proteinminus signligand complexes: applications to drug design. Chem Rev 97, 1359 1472.
129. Han W, Hu Z, Jiang X Decicco CP (2000) Alpha-ketoamides, alpha-ketoesters and alpha-diketones as HCV NS3 protease inhibitors. Bioorg Med Chem Lett 10, 711 713.
130. Yin Z, Patel SJ, Wang WL, Wang G, Chan WL, Rao KR, Alam J, Jeyaraj DA, Ngew X, Patel V et al. (2006) Peptide inhibitors of Dengue virus NS3 protease. Part 1: Warhead. Bioorg Med Chem Lett 16, 36 39.
131. Yin Z, Patel SJ, Wang WL, Chan WL, Ranga Rao KR, Wang G, Ngew X, Patel V, Beer D, Knox Je et al. (2006) Peptide inhibitors of dengue virus NS3 protease. Part 2: SAR study of tetrapeptide aldehyde inhibitors. Bioorg Med Chem Lett 16, 40 43.
132. Ganesh VK, Muller N, Judge K, Luan CH, Padmanabhan R Murthy KH (2005) Identification & characterization of nonsubstrate based inhibitors of the essential dengue and West Nile virus proteases. Bioorg Med Chem 13, 257 264.
133. Kiat TS, Pippen R, Yusof R, Ibrahim H, Khalid N Rahman NA (2006) Inhibitory activity of cyclohexenyl chalcone derivatives and flavonoids of fingerroot, Boesenbergia rotunda (L.), towards dengue-2 virus NS3 protease. Bioorg Med Chem Lett 16, 3337 3340.
134. Angelo PF, Lima AR, Alves FM, Blaber SI, Scarisbrick IA, Blaber M, Juliano L Juliano MA (2006) Substrate specificity of human kallikrein 6: salt and glycosaminoglycan activation effects. J Biol Chem 281, 3116 3126.
135. Notredame C, Higgins D Heringa J (2000) T-Coffee: a novel method for multiple sequence alignments. J Mol Biol 302, 205 217.